[Congressional Record Volume 159, Number 179 (Tuesday, December 17, 2013)]
[Senate]
[Page S8909]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]
TRIBUTE TO VINCENT FORLENZA
Ms. MIKULSKI. Mr. President, Senator Hatch and I join together today
to recognize the contributions of Vincent A. Forlenza, chairman, CEO
and president of BD, in establishing and leading AdvaMedDx, an
important new voice for the role of medical diagnostic tests in patient
care.
BD, the leading global medical technology company, has a strong
presence in both Maryland and Utah as do other companies in the medical
device and diagnostics sectors. We understand firsthand the growing
importance of diagnostics to power medical discoveries and transform
patient care.
Mr. HATCH. The diagnostics sector spans thousands of different kinds
of tests, from blood tests for cholesterol to new genetic tests that
identify cancer variants and match patients to the most appropriate
drugs. Diagnostic tests facilitate evidence-based medicine, improve
quality of care, promote wellness, enable early detection of disease
and often reduce overall health care costs.
In short, diagnostics play a critical role in the health care system
and are an essential part of quality patient care. While these tests
account for only about 2 percent of health care spending, they
influence the large majority of the health care decisions made each and
every day.
Ms. MIKULSKI. The impact of diagnostics, however, is not always well
understood by patients, policymakers and, sometimes, even physicians.
In 2010, Mr. Forlenza played an instrumental role in bringing together
a group of leading diagnostics manufacturers to form a new trade
association, AdvaMedDx, whose core mission is to create an
understanding of the role diagnostics play in the health care system
and help foster patient access to innovative, safe, and effective
tests. Soon after the founding of the AdvaMedDx, Mr. Forlenza assumed
the role of chairman of the board of directors, a position he has held
for the last 3 years.
Mr. HATCH. During Mr. Forlenza's tenure as chairman, AdvaMedDx
doubled the size of its membership and established itself as a credible
voice on health care policy in Washington and around the world. Under
Mr. Forlenza's leadership, the diagnostic industry has worked with a
range of stakeholders to pursue initiatives that aim to reform and
modernize the diagnostics regulatory and payment environment in order
to keep pace with innovation and the changing health care landscape.
AdvaMedDx works not only with Members of Congress and key public health
agencies but also with organizations ranging from patient advocacy
groups to cancer research societies to the World Health Organization.
Ms. MIKULSKI. As part of its contribution to the policy dialogue,
AdvaMedDx has organized Capitol Hill briefings at which leaders in the
field of diagnostics have shared insights and current developments on
topics including women's health, cancer diagnostics, antibiotic
resistance, and infectious diseases. Just a few weeks ago, AdvaMedDx
and the American Association for Cancer Research held a daylong
symposium on personalized medicine and companion diagnostics, keynoted
by the Commissioner of the Food and Drug Administration and the
Director of the National Institutes of Health.
Mr. HATCH. AdvaMedDx also has established itself as a global leader,
driving collaboration with allied associations in Europe, Canada,
Brazil, Japan, and Australia.
Ms. MIKULSKI. Mr. Forlenza has been a tireless champion for the power
of diagnostics to promote wellness, improve patient outcomes and
advance public health. The success of AdvaMedDx in a few short years is
in large measure due to this vision that he brought to the
organization.
Mr. HATCH. Congratulations to Vince on his accomplishments during his
tenure as AdvaMedDx chairman, and best wishes to AdvaMedDx for many
future successes.
____________________